SRCIN1

Summary

SRCIN1 (SRC kinase signaling inhibitor 1, HGNC:29506) is a protein-coding gene on chromosome 17q12, encoding SRC kinase signaling inhibitor 1 (Q9C0H9). Acts as a negative regulator of SRC by activating CSK which inhibits SRC activity and downstream signaling, leading to impaired cell spreading and migration.

Enables protein kinase binding activity. Involved in several processes, including postsynaptic actin cytoskeleton organization; regulation of protein tyrosine kinase activity; and substrate adhesion-dependent cell spreading. Located in actin cytoskeleton and cytoplasm. Is active in glutamatergic synapse.

Source: NCBI Gene 80725 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 174 total
• Druggable target: yes
• MANE Select transcript: NM_025248

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29506
Approved symbol	SRCIN1
Name	SRC kinase signaling inhibitor 1
Location	17q12
Locus type	gene with protein product
Status	Approved
Aliases	SNIP, p140Cap, KIAA1684
Ensembl gene	ENSG00000277363
Ensembl biotype	protein_coding
OMIM	610786
Entrez	80725

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 6 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000612208, ENST00000612431, ENST00000613927, ENST00000617146, ENST00000621275, ENST00000621492, ENST00000621763, ENST00000622190, ENST00000622519

RefSeq mRNA: 1 — MANE Select: NM_025248 NM_025248

CCDS: CCDS45660

Canonical transcript exons

ENST00000615049 — 0 exons

Expression profiles

Bgee: expression breadth ubiquitous, 129 present calls, max score 97.58.

FANTOM5 (CAGE): breadth broad, TPM avg 7.4933 / max 451.6762, expressed in 815 samples.

FANTOM5 promoters (17 alternative TSS)

Promoter ID	TPM avg	Samples expressed
165527	3.3358	574
165509	0.7879	321
165524	0.5523	95
165528	0.4678	225
165521	0.4659	94
165522	0.4013	101
165517	0.3523	85
165516	0.2658	106
165511	0.1644	16
165519	0.1344	57

Top tissues by expression

132 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
C1 segment of cervical spinal cord	UBERON:0006469	97.58	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.29	gold quality
cerebellum	UBERON:0002037	96.22	gold quality
cerebellar cortex	UBERON:0002129	96.20	gold quality
cerebellar hemisphere	UBERON:0002245	96.16	gold quality
substantia nigra	UBERON:0002038	95.44	gold quality
Ammon’s horn	UBERON:0001954	95.14	gold quality
primary visual cortex	UBERON:0002436	95.13	gold quality
prefrontal cortex	UBERON:0000451	93.22	gold quality
Brodmann (1909) area 9	UBERON:0013540	92.95	gold quality
temporal lobe	UBERON:0001871	92.89	gold quality
hypothalamus	UBERON:0001898	92.86	gold quality
superior frontal gyrus	UBERON:0002661	92.83	gold quality
amygdala	UBERON:0001876	92.82	gold quality
frontal cortex	UBERON:0001870	92.74	gold quality
cerebral cortex	UBERON:0000956	92.49	gold quality
brain	UBERON:0000955	92.36	gold quality
putamen	UBERON:0001874	92.33	gold quality
right frontal lobe	UBERON:0002810	92.04	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	91.71	gold quality
anterior cingulate cortex	UBERON:0009835	91.21	gold quality
pituitary gland	UBERON:0000007	90.27	gold quality
caudate nucleus	UBERON:0001873	89.42	gold quality
cortical plate	UBERON:0005343	89.33	gold quality
right uterine tube	UBERON:0001302	88.80	gold quality
adenohypophysis	UBERON:0002196	88.69	gold quality
nucleus accumbens	UBERON:0001882	88.22	gold quality
corpus callosum	UBERON:0002336	88.17	gold quality
right lobe of liver	UBERON:0001114	86.63	gold quality
ganglionic eminence	UBERON:0004023	84.44	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.15

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

161 targeting SRCIN1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872

Literature-anchored findings (GeneRIF, showing 24)

• provides the first evidence that p140Cap is a novel negative regulator of tumour growth (PMID:17525734)
• Expression correlated significantly with unfavourable overall survival, suggesting that SNIP/p140Cap may be a useful diagnostic and prognostic marker, aas well as therapeutic target, in breast cancer. (PMID:18475297)
• p140Cap immobilizes E-cadherin at the cell membrane and inhibits EGFR and Erk1/2 signalling, blocking scatter and proliferation of cancer cells. (PMID:20453886)
• p140Cap phosphorylation sites and binding to Csk and Abl kinase (PMID:23383002)
• Findings indicate the role of miR-150 as an oncogene in lung cancer through the inhibition of SRC kinase signalling inhibitor 1 (SRCIN1) translation. (PMID:24456795)
• these findings suggest that miR-374a functions as a candidate oncogene in GC by directly targeting SRCIN1 (PMID:25554419)
• these results reveal a novel function of postsynaptic endophilin A1 in spine morphogenesis, stabilization and synaptic function through the regulation of p140Cap (PMID:25771685)
• miR-211 may function as an oncogenic miRNA in non-small cell lung cancer, partly by regulating SRCIN1 (PMID:26277787)
• miR-346 may function as an oncogenic miRNA and mediate chemosensitivity to docetaxel through targeting SRCIN1 in breast cancer (PMID:27913185)
• Data indicate that the major mechanism is the ability of p140Cap to interfere with ERBB2-dependent activation of Rac GTPase-controlled circuitries. (PMID:28300085)
• Together, these results demonstrate that Srcin1 contributes to CRC carcinogenesis, invasion and metastasis. These findings provide a rationale for a mechanistic approach to CRC treatment based on the development of Srcin1-targeted therapies (PMID:28393242)
• Study demonstrates a critical role of presynaptic cadherin/catenin/p140Cap cell adhesion complexes in stabilizing functional synapses and spines in the developing neocortex. (PMID:28641114)
• These findings suggest that the miR-17-5p promotes cell proliferation, and EMT in human OS by directly targeting the SRCIN1, and reveal a branch of the miR-17-5p/SRCIN1/EMT signaling pathway involved in the progression of osteosarcoma. (PMID:30302813)
• Upregulation of miR-150 promoted angiogenesis and proliferation of endothelial progenitor cells by targeting SRCIN1 in vitro and thrombus resolution in vivo. (PMID:30315850)
• this study revealed that miR-374a promoted cell proliferation, migration and EMT via targeting SRCIN1 in pancreatic cancer (PMID:30890278)
• The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma. (PMID:31285546)
• Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1. (PMID:31385464)
• the present study is the first to provide evidence that miR208a exerts oncogenic functions in the carcinogenesis and progression of nonsmall cell lung cancer by directly targeting SRCIN1 and regulating the ERK pathway. (PMID:31432113)
• lncRNA TPTEP1 competitively sponges miR3285p to inhibit the proliferation of nonsmall cell lung cancer cells. (PMID:32323798)
• FOXD3-AS1 suppresses the progression of non-small cell lung cancer by regulating miR-150/SRCIN1axis. (PMID:32924985)
• SRCIN1 Regulated by circCCDC66/miR-211 Is Upregulated and Promotes Cell Proliferation in Non-Small-Cell Lung Cancer. (PMID:32964035)
• The p140Cap adaptor protein as a molecular hub to block cancer aggressiveness. (PMID:33079227)
• p140Cap inhibits beta-Catenin in the breast cancer stem cell compartment instructing a protective anti-tumor immune response. (PMID:37169737)
• Hypermethylation of the Gene Body in SRCIN1 Is Involved in Breast Cancer Cell Proliferation and Is a Potential Blood-Based Biomarker for Early Detection and a Poor Prognosis. (PMID:38785978)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	srcin1a	ENSDARG00000059773
danio_rerio	srcin1b	ENSDARG00000101812
mus_musculus	Srcin1	ENSMUSG00000038453
rattus_norvegicus	Srcin1	ENSRNOG00000011475
drosophila_melanogaster	CG32809	FBGN0023531
caenorhabditis_elegans		WBGENE00022180

Paralogs (1): KIAA1217 (ENSG00000120549)

Protein

Protein identifiers

SRC kinase signaling inhibitor 1 — Q9C0H9 (reviewed: Q9C0H9)

Alternative names: SNAP-25-interacting protein, p130Cas-associated protein, p140Cap

All UniProt accessions (6): Q9C0H9, A0A087WTE6, A0A087WU33, A0A087WVV7, A0A087X165, A0A590UJ70

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a negative regulator of SRC by activating CSK which inhibits SRC activity and downstream signaling, leading to impaired cell spreading and migration. Regulates dendritic spine morphology. Involved in calcium-dependent exocytosis. May play a role in neurotransmitter release or synapse maintenance.

Subunit / interactions. Interacts with the N-terminal coiled-coil region of SNAP25. Interacts with BCAR1/p130Cas and SRC through its C-terminal domain. Interacts with CSK, CTTN, SORBS3/vinexin, SYP and MAPRE3/EB3.

Subcellular location. Cytoplasm. Cytoskeleton. Cell projection. Axon. Dendrite. Presynapse. Postsynapse. Postsynaptic density.

Tissue specificity. Expressed in some primary breast carcinomas where its presence is significantly associated with increased tumor size. Not detected in normal breast tissue.

Post-translational modifications. Tyrosine-phosphorylated in response to EGF and to cell adhesion to integrin ligands.

Similarity. Belongs to the SRCIN1 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9C0H9-5	1	yes
Q9C0H9-2	2
Q9C0H9-4	3

RefSeq proteins (1): NP_079524* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR022782	AIP3-like_C	Domain
IPR051825	SRCIN1	Family

Pfam: PF03915

UniProt features (81 total): modified residue 41, sequence conflict 13, compositionally biased region 11, region of interest 8, splice variant 5, coiled-coil region 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9C0H9-F1	55.20	0.20

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (41): 13, 18, 45, 52, 53, 64, 143, 165, 169, 179, 225, 241, 298, 307, 324, 329, 336, 343, 362, 364 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 240 (showing top): GOBP_DENDRITE_DEVELOPMENT, GOBP_REGULATION_OF_PROTEIN_TYROSINE_KINASE_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_PEPTIDYL_TYROSINE_PHOSPHORYLATION, MYOGENIN_Q6, GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_NEGATIVE_REGULATION_OF_KINASE_ACTIVITY, MIDORIKAWA_AMPLIFIED_IN_LIVER_CANCER, GOBP_DENDRITIC_SPINE_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_TYROSINE_KINASE_ACTIVITY, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, GOBP_NEUROGENESIS, TGACCTY_ERR1_Q2, GOBP_VESICLE_MEDIATED_TRANSPORT, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5

GO Biological Process (7): exocytosis (GO:0006887), regulation of cell migration (GO:0030334), substrate adhesion-dependent cell spreading (GO:0034446), regulation of dendritic spine morphogenesis (GO:0061001), positive regulation of protein tyrosine kinase activity (GO:0061098), negative regulation of protein tyrosine kinase activity (GO:0061099), postsynaptic actin cytoskeleton organization (GO:0098974)

GO Molecular Function (2): protein kinase binding (GO:0019901), protein binding (GO:0005515)

GO Cellular Component (11): cytoplasm (GO:0005737), postsynaptic density (GO:0014069), actin cytoskeleton (GO:0015629), axon (GO:0030424), dendrite (GO:0030425), synapse (GO:0045202), presynapse (GO:0098793), glutamatergic synapse (GO:0098978), cytoskeleton (GO:0005856), cell projection (GO:0042995), postsynapse (GO:0098794)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
synapse	3
protein tyrosine kinase activity	2
regulation of protein tyrosine kinase activity	2
neuron projection	2
vesicle-mediated transport	1
secretion by cell	1
vesicle fusion to plasma membrane	1
cell migration	1
regulation of cell motility	1
cell-substrate adhesion	1
regulation of neuron projection development	1
regulation of anatomical structure morphogenesis	1
dendritic spine morphogenesis	1
regulation of postsynapse organization	1
positive regulation of protein kinase activity	1
positive regulation of peptidyl-tyrosine phosphorylation	1
negative regulation of protein kinase activity	1
negative regulation of peptidyl-tyrosine phosphorylation	1
actin cytoskeleton organization	1
postsynaptic cytoskeleton organization	1
kinase binding	1
binding	1
intracellular anatomical structure	1
asymmetric synapse	1
postsynaptic specialization	1
cytoskeleton	1
dendritic tree	1
cell junction	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1064 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SRCIN1	HCLS1	P14317	911
SRCIN1	CTTN	Q14247	911
SRCIN1	MAPRE3	Q9UPY8	908
SRCIN1	DLG4	P78352	674
SRCIN1	SRC	P12931	636
SRCIN1	SNAP25	P13795	578
SRCIN1	BCAR1	P56945	558
SRCIN1	NEXN	Q0ZGT2	537
SRCIN1	CSK	P41240	528
SRCIN1	ARHGAP23	Q9P227	489
SRCIN1	BUD13	Q9BRD0	467
SRCIN1	CDC42BPB	Q9Y5S2	466
SRCIN1	SNIP1	Q8TAD8	447
SRCIN1	ROCK1	Q13464	427
SRCIN1	TTC36	A6NLP5	422

IntAct

36 interactions, top by confidence:

A	B	Type	Score
SYNGAP1	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
NUFIP1	PDE2A	psi-mi:“MI:0914”(association)	0.530
SRCIN1	BCAR1	psi-mi:“MI:0915”(physical association)	0.460
BCAR1	SRCIN1	psi-mi:“MI:0915”(physical association)	0.460
SRCIN1	BCAR1	psi-mi:“MI:0403”(colocalization)	0.460
Bcar1	SRCIN1	psi-mi:“MI:0915”(physical association)	0.400
SRCIN1	SRC	psi-mi:“MI:0915”(physical association)	0.400
SRC	SRCIN1	psi-mi:“MI:0915”(physical association)	0.400
CSK	SRC	psi-mi:“MI:0915”(physical association)	0.400
CEP192	WASL	psi-mi:“MI:0914”(association)	0.350
ANK2	IGKV2-40	psi-mi:“MI:0914”(association)	0.350
SHANK3	IGKV3D-15	psi-mi:“MI:0914”(association)	0.350
DYRK1A	TEX13D	psi-mi:“MI:0914”(association)	0.350
ITM2B	ILVBL	psi-mi:“MI:0914”(association)	0.350
RIMS1	KIF2A	psi-mi:“MI:0914”(association)	0.350
CUL3	KIF21B	psi-mi:“MI:0914”(association)	0.350
CACNA1C	IGLL5	psi-mi:“MI:0914”(association)	0.350
SYNGAP1	POTEF	psi-mi:“MI:0914”(association)	0.350
RIMS1	PSMD12	psi-mi:“MI:0914”(association)	0.350
SYNGAP1	POM121C	psi-mi:“MI:0914”(association)	0.350
HCN1	POTEF	psi-mi:“MI:0914”(association)	0.350
SYNGAP1	IGLON5	psi-mi:“MI:0914”(association)	0.350
MIF	BLTP3B	psi-mi:“MI:0914”(association)	0.350
KRT40	ANKRD36	psi-mi:“MI:0914”(association)	0.350
GPM6A	KIF2A	psi-mi:“MI:0914”(association)	0.350
BRK1	KIF5C	psi-mi:“MI:0914”(association)	0.350
BCAS4	SNAPIN	psi-mi:“MI:0914”(association)	0.350

BioGRID (49): SRCIN1 (Affinity Capture-MS), SRCIN1 (Affinity Capture-MS), CKAP5 (Co-fractionation), SRCIN1 (Proximity Label-MS), SRCIN1 (Affinity Capture-MS), SRCIN1 (Affinity Capture-MS), SRCIN1 (Affinity Capture-RNA), SRCIN1 (Biochemical Activity), SRCIN1 (Affinity Capture-MS), SRCIN1 (Affinity Capture-MS), SRCIN1 (Affinity Capture-Western), BCAR1 (Affinity Capture-Western), CRK (Affinity Capture-Western), BCAR1 (Reconstituted Complex), CSK (Far Western)

ESM2 similar proteins: A0A8I3QA39, A1YB07, A2A6T1, A2A9T0, A2AHG0, A5PKL7, A6NKD9, A7MCY6, B8A5S6, D3ZD05, E1BEQ5, E1U8D0, E9Q6B2, F1MRK3, G3V735, O14529, O60299, O75145, O94964, P60469, Q1LZH7, Q3LUD4, Q3UIL6, Q499E4, Q5JTD0, Q5RCR6, Q5XIA0, Q62036, Q63ZY3, Q6DG50, Q6IQ23, Q6NZT2, Q6PDH0, Q86UU1, Q86X02, Q8BX02, Q8C7U1, Q8IY63, Q8K1Q4, Q8K371

Diamond homologs: A2AQ25, Q5T5P2, Q9C0H9, Q9QWI6, Q9QXY2, Q7PQ25

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
ABL1	unknown	SRCIN1	phosphorylation
SRC	“up-regulates activity”	SRCIN1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

174 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	150
Likely benign	5
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

5263 predictions. Top by Δscore:

Variant	Effect	Δscore
17:38543817:CCTCA:C	donor_loss	1.0000
17:38543818:CTCA:C	donor_loss	1.0000
17:38543819:TCA:T	donor_loss	1.0000
17:38543820:CAC:C	donor_loss	1.0000
17:38543821:ACCT:A	donor_loss	1.0000
17:38548553:CTAC:C	donor_loss	1.0000
17:38548555:A:AC	donor_gain	1.0000
17:38548555:ACC:A	donor_loss	1.0000
17:38548556:C:CC	donor_gain	1.0000
17:38548556:CCT:C	donor_gain	1.0000
17:38548705:GCCTT:G	acceptor_gain	1.0000
17:38548706:CCTTC:C	acceptor_gain	1.0000
17:38548707:CTT:C	acceptor_gain	1.0000
17:38548708:TT:T	acceptor_gain	1.0000
17:38548710:C:CC	acceptor_gain	1.0000
17:38551895:CACAG:C	donor_gain	1.0000
17:38551899:G:C	donor_gain	1.0000
17:38552591:TGAG:T	acceptor_gain	1.0000
17:38552592:GAG:G	acceptor_gain	1.0000
17:38552592:GAGC:G	acceptor_loss	1.0000
17:38552594:GCT:G	acceptor_loss	1.0000
17:38552595:C:CC	acceptor_gain	1.0000
17:38552723:A:AC	donor_gain	1.0000
17:38552723:AC:A	donor_gain	1.0000
17:38552723:ACC:A	donor_gain	1.0000
17:38552724:C:CA	donor_gain	1.0000
17:38552724:C:CC	donor_gain	1.0000
17:38552724:CCC:C	donor_gain	1.0000
17:38552851:GGTCA:G	acceptor_gain	1.0000
17:38552853:TCA:T	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000079066 (17:38556794 C>A,G,T), RS1000101647 (17:38546266 G>T), RS1000123512 (17:38589195 C>T), RS1000139137 (17:38595272 C>A,T), RS1000180410 (17:38569758 A>G), RS1000188541 (17:38530379 C>A,T), RS1000250294 (17:38558787 G>A), RS1000263158 (17:38566864 C>T), RS1000325082 (17:38551493 G>A), RS1000365114 (17:38530192 G>A), RS1000377717 (17:38540933 T>G), RS1000386620 (17:38558452 A>C,T), RS1000426339 (17:38569493 G>A), RS1000436555 (17:38589570 T>C), RS1000504669 (17:38581153 T>A)

Disease associations

OMIM: gene MIM:610786 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009557_12	Rate of ventricular enlargement	9.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0010570	ventricular enlargement measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2150836 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, increases methylation	4
mercuric bromide	decreases expression, affects cotreatment	2
Panobinostat	affects cotreatment, decreases expression	2
Benzo(a)pyrene	affects methylation, increases methylation	2
Nickel	decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Silicon Dioxide	decreases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
FR900359	affects phosphorylation	1
methylmercuric chloride	decreases expression	1
propionaldehyde	increases expression	1
dimethylselenide	increases expression, increases oxidation	1
arsenite	affects binding, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	decreases expression	1
aflatoxin B2	increases methylation	1
CGP 52608	affects binding, increases reaction	1
tanespimycin	increases expression, affects cotreatment	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
STA 9090	increases expression	1
VER 155008	affects cotreatment, increases expression	1
Fulvestrant	decreases methylation	1
Vorinostat	decreases expression	1
Acetaminophen	decreases expression	1
Caffeine	affects phosphorylation	1
Cocaine	decreases reaction, increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Lead	affects expression	1
Phthalic Acids	decreases methylation	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2157707	Binding	Inhibition of SrcN1 at 1 uM	Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf. — Bioorg Med Chem Lett

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.